Human Laboratory Studies on Cannabinoids and Psychosis

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Cannabinoid agonists are increasingly linked to psychosis.
• Controlled studies are crucial for understanding these effects.

Purpose of the Study:

• To investigate the psychotomimetic effects of cannabinoid agonists in humans.
• To compare these effects with other psychotomimetic drugs.
• To examine vulnerability in schizophrenia patients.

Main Methods:

• Randomized, double-blind, placebo-controlled, crossover laboratory studies.
• Administration of phytocannabinoids and synthetic cannabinoids.
• Assessment of positive, negative, and cognitive symptoms and psychophysiologic deficits.

Main Results:

• Cannabinoid agonists produced transient, dose-related psychosis-like symptoms in healthy subjects.
• Schizophrenia patients showed increased vulnerability and symptom exacerbation.
• No beneficial effects were observed in schizophrenia patients, challenging self-medication hypotheses.
• Genetic polymorphisms may moderate cannabinoid agonist effects.

Conclusions:

• Cannabinoid agonists can induce and exacerbate psychosis-like symptoms.
• Schizophrenia patients are particularly vulnerable to these effects.
• Cannabis self-medication hypothesis is not supported by current evidence.